ClinicalTrials.gg
Status unknownNCT00563017Updated Jul 7, 2010

Evaluation of Efficacy and Safety of Long-acting Risperidone Microspheres in Patients With Schizophrenia or Other Psychotic Disorders When Switching From Typical Antipsychotic (Oral/Depot) or Atypical Oral Other Than Risperidone

An interventional study of Long-acting Risperidone microspheres injection in Schizophrenia, Catatonic, Schizophrenia, Disorganized and Schizophrenia, Paranoid, sponsored by Hospital Authority, Hong Kong. Status unknown at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-07-07.

Sponsored by Hospital Authority, Hong Kong · Not applicable, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Jul 2010), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 252 studies in Schizophrenia with a site in China — 64 open to participants now, 68 under way, 4 of them phase 3. Schizophrenia · China.

Planned enrollment
196th of 216
30 · median 100
Started
2004
with 2 others
No phase
110 of 252
36 open now
Registered
8th of 252
by date

Among the 252 studies in Schizophrenia with a site in China, this one is the 196th largest by planned enrollment of the 216 interventional ones that give a count, is one of 3 that started in 2004, is one of 110 with no phase, and was the 8th registered.

Schizophrenia

3,574 studies on the registry are indexed under Schizophrenia; 496 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

64 of the 252 studies in Schizophrenia with a site in China are open now. Recruiting first, the newest first:

59 more — sign in →

All 64 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 334 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 259 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 252 studies in Schizophrenia with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy, tolerability and safety of patients on long-acting Risperidone microshpheres injection. The major advantage of long-acting injection over oral medication is facilitation of compliance in medication taking. Non-compliance is very common among schizophrenic and is a frequent cause of relapse.

03

Conditions studied

  • Schizophrenia, Catatonic
  • Schizophrenia, Disorganized
  • Schizophrenia, Paranoid
  • Schizophrenia
  • Psychotic Disorders

Keywords

  • Catatonic Schizophrenia
  • Disorganized Schizophrenia
  • Paranoid Schizophrenia
  • Undifferentiated Schizophrenia
  • Schizo-affective disorders
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects with schizophrenia or another psychotic disorder according to DSM IV criteria who requires long term antipsychotic therapy
  • Currently treated with either an atypical antipsychotic, other than risperidone, a conventional depot antipsychotic or oral conventional antipsychotic
  • Subject has been symptomatically stable on a stable dose of an antipsychotic the last month
  • Subject and/or patient's relative, guardian or legal representative has signed the form

Exclusion criteria

Exclusion Criteria:

  • First antipsychotic treatment ever
  • On clozapine during the last 3 month
  • Serious unstable medical condition
  • History or current symptoms of tardive dyskinesia
  • History of neuroleptic malignant syndrome
  • Pregnant or breast-feeding female
  • Female patient of without adequate .
  • Participation in an drug trial in the 30 days prior to selection
  • Known intolerance/non-responder to risperidone
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Enrollment
30 participants (estimated)

Interventions

  • DrugLong-acting Risperidone microspheres injection
06

What researchers measure

Primary outcomes

  1. Efficacy/ Clinical Global Impression

    Time frame: Week 0, 4, 8,12

  2. Personal and Social Performance Scale

    Time frame: Week 0, 12

  3. Extrapyramidal Symptom

    Time frame: Week 0, 4, 8,12

Secondary outcomes

  1. +Quality of life SF-36

    Time frame: Week 0,12

  2. Pain assoicated with injection VAS

    Time frame: Week 0, 4, 8, 12

07

Study locations

1 of 1 sites recruiting
  • Kwai Chung Hospital
    Hong Kong, China
    Recruiting
    • Gloria FY Chan, Dr · Sub investigator
    • Ming-ming Chan, Dr · Sub investigator
    • Vincent WH Chan, Dr · Sub investigator
    • Tin-sung Tam, Dr · Sub investigator
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2004 and a completion of Nov 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2007
First posted
Nov 26, 2007
Start
Oct 2004
CompletionEst.
Nov 2005
Last update
Jul 7, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 7, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00563017
Lead sponsor
Hospital Authority, Hong Kong
First posted
Nov 26, 2007
Start date
Oct 2004
Completion
Nov 2005 (estimated)
Last update
Jul 7, 2010

Study contacts

Wing King Lee, Dr
Contact
drwklee@gmail.com
(852) 2388 8559 ext. 269
Wing King Lee, Dr
principal investigator · Yaumatei Psychiatric Center, Kwai Chung Hospital
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jul 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion